Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 13/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327387 | 0.89 | ESR2 (0.37) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL12299741 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL4784162 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA2CA9 | |
| SCHEMBL30345343 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL29975527 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA2CA9 | |
| SCHEMBL3323420 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL12522631 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL419330 | 0.88 | LPL (0.45) | ESR2LPLLIPGPGR | |
| SCHEMBL30169943 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL28779 | 0.88 | ESR2 (0.36) | ESR2LPLLIPGPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | NXERA PHARMA UK LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| WO-2025057775-A1 | MATERIAL FOR PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING ELEMENT, AND IMAGING ELEMENT | 東ソー株式会社 | 2025-03-20 | — | — | WO | disclosed |
| US-12122768-B2 | Benzonitrile derivative, light-emitting material, and light-emitting element using same | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2024-10-22 | — | — | US | disclosed |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2024-03-21 | — | — | US | disclosed |
| CN-116554057-B | Compounds for reducing Erythropoietin (EPO) production and uses thereof | 杭州安道药业有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| CN-116554057-A | Compounds for reducing Erythropoietin (EPO) production and uses thereof | 杭州安道药业有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2655378-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122768-B2 | Benzonitrile derivative, light-emitting material, and light-emitting element using same | INTS9, GTF2I, BRI3BP | ESR2 955/4885LPL 2153/4885LIPG 2363/4885 |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | ESR2 2144/4885LPL 1639/4885LIPG 1531/4885 |
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAT1, FTO, SETDB1 | ESR2 1202/4885LPL 3097/4885LIPG 2289/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | ESR2 2312/4885LPL 1307/4885LIPG 578/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | ESR2 2312/4885LPL 1307/4885LIPG 578/4885 |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | ESR2 608/4885LPL 1075/4885LIPG 2341/4885 |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | ESR2 608/4885LPL 1075/4885LIPG 2341/4885 |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM6, GRM2 | ESR2 620/4885LPL 1073/4885LIPG 2273/4885 |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | ESR2 620/4885LPL 1073/4885LIPG 2273/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | ESR2 1890/4885LPL 869/4885LIPG 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.